# A Phase 2 Study of BB102 in Patients With Hepatocellular Carcinoma

> **NCT07239986** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Broadenbio Ltd., Co.** · enrollment: 60 (estimated)

## Conditions studied

- Hepatocellular Carcinoma (HCC)

## Interventions

- **DRUG:** BB102

## Key facts

- **NCT ID:** NCT07239986
- **Lead sponsor:** Broadenbio Ltd., Co.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-12
- **Primary completion:** 2027-06
- **Final completion:** 2028-06
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-11-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07239986

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07239986, "A Phase 2 Study of BB102 in Patients With Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT07239986. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*